Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Inclusion Criteria:

• Have histologically or cytologically confirmed PDAC that is metastatic.

• Have not been previously treated for PDAC in the metastatic setting.

1. Prior neoadjuvant and/or adjuvant therapy for PDAC is permitted if completed atleast 12 months before randomization.

2. Prior palliative radiotherapy is allowed if completed at least 2 weeks prior torandomization and AEs have resolved to Grade 1 or less before randomization.

3. Prior and/or placement of a biliary stent/tube is permitted if anytreatment-related AEs have improved to Grade ≤ 1 and the patient is notexhibiting any signs/symptoms of biliary obstruction.

• Eastern Cooperative Oncology Group PS of 0 to 1.

• At least 1 target lesion measurable by computed tomography (CT)/magnetic resonanceimaging (MRI) per RECIST v1.1. not within a field of prior radiation therapy.

Exclusion Criteria:

• Previously treated for locally advanced, unresectable PDAC.

• History of brain metastases or leptomeningeal metastases.

• Prior treatment with a CD73 antagonist or inhibitor.

• Underlying medical conditions that, in the investigator or sponsor's opinion, willmake the administration of study-specified therapy hazardous

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.